a public good project by the
Synthesis
Company
of California

© 2026

Ray McDermott | doi.page

0 works0 citations0 h-index

Ray McDermott

Cancer Trials Ireland(IE)St. Vincent's University Hospital(IE)

Publications by Year

Research Areas

Prostate Cancer Treatment and Research, Cancer Immunotherapy and Biomarkers, PARP inhibition in cancer therapy, Colorectal Cancer Treatments and Studies, Cancer Genomics and Diagnostics

Most-Cited Works

→ Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma(2015)5,839 cited
→ Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma(2018)4,536 cited
→ Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma(2019)3,317 cited
→ Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study(2017)2,758 cited
→ Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal Cancer(2018)2,022 cited
→ Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer(2019)1,551 cited

→ Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial(2018)

1,309 cited

→ Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma(2021)986 cited

→ Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials(2020)963 cited

→ Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design(2022)735 cited